Today, we are excited to announce our latest investment in Idoven, a pioneering health tech company advancing early detection of and precision medicine for cardiovascular disease. We are co-leading this investment with Insight Partners and with the participation of Wayra and existing investors. Business angels joining this round include Ron Vianu (Covera Health), Brad Fluege (ex-Walgreens) and Vlad Lata (Avi Medical).
The company closed this $19.8 million Series A to expand its services across Europe and the US and to further develop the company’s AI, cloud-based solution. The proprietary technology identifies arrhythmias and cardiac abnormalities from electrocardiograms (ECGs), and scales the company’s precision medicine capacities.
Electrocardiograms are one of the most common tests administered by physicians globally, as arrhythmias can be indicative of cardiovascular disease. Cardiologists spend millions of hours globally interpreting ECGs, and while there have been advances to automate these processes, none have done so with the breadth and accuracy achieved by Idoven. Their product brings a deep-learning-based model to its intervention, powered by the most comprehensive ECG database known to the field. Idoven has been able to build its database through a hardware-agnostic approach. Our investor Pascual Cortes-Monroy shares more about our investment thesis here.
Cardiovascular disease is expected to account for €1 trillion in costs to the public health system, and as the population grows older, the need to manage this health challenge compounds. By delivering diagnostics in minutes with clinical-level accuracy, Idoven is tackling the number one cause of death globally and curbing the biggest cost driver in our healthcare systems.
Our partner, Michiel Kotting, also adds: “Starting with cardiologist-level accuracy in seconds and at scale for hospital ECGs (electrocardiograms), and ending with cost and delay reduction, the database Idoven is building up will enable the detection of potential heart problems in advance and even on everyday fitness trackers. We are incredibly proud and excited to join the team on this journey.”
The founding team has impressed us from the beginning and consists of: Dr Manuel Marina Breysse (CEO and cardiologist), José Maria Lillo Castellano (CTO and researcher at the National Centre for Cardiovascular Research), and Iñigo Juantegui (serial entrepreneur, Rocket Internet, Ontruck). The team have also managed to surround themselves with top tier talent, including seasoned operator Rika Christanto, a previous founder and founding member on Ontruck.
We’re thrilled to partner with Idoven as they tackle this global health challenge!